ReviewCureus2025
Remimazolam as a Novel Option for Procedural Sedation: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Procedural sedation (PS) is a widely used practice designed to relieve anxiety, induce amnesia, and improve patient comfort during diagnostic and therapeutic procedures, particularly those that may cause discomfort. The choice of sedative agent plays a critical role in determining the depth of sedation, recovery time, and risk of adverse effects. Traditionally, midazolam, a benzodiazepine (BDZ), has been the agent of choice for PS due to its rapid onset and relatively short duration of action. However, midazolam's active metabolites can result in prolonged sedation, posing a risk of delayed recovery and increased complications. These drawbacks have sparked interest in the development of alternatives that offer a more favorable pharmacokinetic profile. Remimazolam, a novel ultra-short-acting BDZ, has emerged as a potential solution. Unlike midazolam, remimazolam has a rapid onset of action, a very short duration of effect, and no active metabolites, which significantly reduces the risk of prolonged sedation and enhances patient safety. Its unique pharmacological properties make it a promising candidate for PS, particularly in outpatient and short-duration procedures where rapid recovery is critical. This narrative review aims to evaluate the available literature on remimazolam as an agent for PS, with a focus on its pharmacology, safety profile, and clinical efficacy. A comprehensive literature search was conducted on PubMed and Google Scholar, focusing on studies published between 2015 and 2025. The review encompasses original research articles, clinical trials, systematic reviews, and preclinical studies that compare remimazolam with other sedatives, including midazolam, propofol, and ketamine. The findings from these studies were synthesized to highlight the advantages of remimazolam, including its rapid onset, short duration, and safety profile. Emphasis was placed on clinical studies assessing its efficacy in various procedural contexts, identifying gaps in the current evidence, and suggesting directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.